Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of “Buy” from Analysts

Aura Biosciences, Inc. (NASDAQ:AURA) has been given a consensus rating of “Buy” by the eight ratings firms that are covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $22.00.

AURA has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research note on Wednesday, August 13th. JMP Securities reiterated a “market outperform” rating and set a $19.00 price target on shares of Aura Biosciences in a research note on Friday, May 23rd.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $6.70, for a total value of $51,737.40. Following the completion of the transaction, the senior vice president owned 86,558 shares in the company, valued at $579,938.60. This trade represents a 8.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AURA. Vanguard Group Inc. boosted its stake in Aura Biosciences by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company’s stock worth $15,764,000 after purchasing an additional 112,296 shares during the period. JPMorgan Chase & Co. boosted its stake in Aura Biosciences by 76.4% in the 4th quarter. JPMorgan Chase & Co. now owns 94,386 shares of the company’s stock worth $776,000 after purchasing an additional 40,884 shares during the period. Geode Capital Management LLC boosted its stake in Aura Biosciences by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company’s stock worth $8,327,000 after purchasing an additional 3,972 shares during the period. Wells Fargo & Company MN boosted its stake in Aura Biosciences by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company’s stock worth $227,000 after purchasing an additional 5,930 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Aura Biosciences by 489.4% in the 4th quarter. Renaissance Technologies LLC now owns 83,700 shares of the company’s stock worth $688,000 after purchasing an additional 69,500 shares during the period. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $6.37 on Thursday. The company has a market capitalization of $395.70 million, a PE ratio of -3.25 and a beta of 0.46. The business has a fifty day moving average price of $6.61 and a two-hundred day moving average price of $6.50. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Sell-side analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.